Current development of CBP/p300 inhibitors in the last decade
CBP/p300, functioning as histone acetyltransferases and transcriptional co-factors, represents a beautiful target for a number of illnesses, including malignant tumor. The introduction of small-molecule inhibitors individuals bromodomain and HAT domains of CBP/p300 has turned on broad interests of medicinal chemist in expectation of supplying new expect anti-cancer treatment. Particularly, the CBP/p300 bromodomain inhibitor CCS1477, recognized by CellCentric, is presently gone through clinical evaluation to treat haematological malignancies and cancer of the prostate. Within this review, we illustrate the introduction of CBP/p300 inhibitors reported from 2010 to 2020 especially highlight their structure-activity relationships (SARs), binding modes, selectivity and medicinal functions for the exact purpose to facilitate rational development and design of CBP/p300 inhibitors.